Characteristics of the study cohorts in the primary study period 1998–2014 and in the sensitivity analysis study period 1987–2014
| Follow-up 1998–2014 | Follow-up 1987–2014 | |||||
| Patients with NF1 | Controls | Siblings without NF1 | Patients with NF1 | Controls | Siblings without NF1 | |
| n | 1349 | 13 870 | 1871 | 1410 | 14 017 | 1881 |
| Sex | ||||||
| Females, n (%) | 694 (51.4) | 7189 (51.8) | 893 (47.7) | 732 (51.9) | 7256 (51.8) | 895 (47.6) |
| Males, n (%) | 655 (48.6) | 6681 (48.2) | 978 (52.3) | 678 (48.1) | 6761 (48.2) | 986 (52.4) |
| Year of birth, mean (SD) | 1975.2 (21.6) | 1974.4 (22.0) | 1976.5 (18.5) | 1974.0 (22.4) | 1974.0 (22.4) | 1976.4 (18.5) |
| Start of follow-up (cohort entry) | ||||||
| Age, mean (SD) | 25.7 (20.7) | 26.3 (21.0) | 24.4 (17.4) | 23.6 (20.7) | 23.6 (20.7) | 21.5 (16.7) |
| Year, mean (SD) | 2001.1 (4.2) | 2001.0 (4.1) | 2001.1 (4.1) | 1997.6 (7.3) | 1997.6 (7.3) | 1997.9 (7.2) |
| End of follow-up | ||||||
| Age, mean (SD) | 38.3 (20.8) | 39.7 (21.5) | 37.8 (18.4) | 38.6 (21.0) | 40.0 (21.6) | 37.7 (18.4) |
| Year, mean (SD) | 2013.1 (2.8) | 2013.7 (1.8) | 2013.7 (1.5) | 2012.2 (4.9) | 2013.5 (2.7) | 2013.6 (2.1) |
| Follow-up time, mean (SD) | 12.7 (4.9) | 13.4 (4.5) | 13.4 (4.4) | 15.0 (7.5) | 16.3 (7.4) | 16.2 (7.2) |
NF1, neurofibromatosis type 1.